Next Article in Journal
The Role of Cone Beam Computed Tomography in Periodontology: From 3D Models of Periodontal Defects to 3D-Printed Scaffolds
Next Article in Special Issue
Personalized Research on the Aging Face—A Narrative History
Previous Article in Journal
Laparoscopic Management of Multiple Liver, Omental, Mesenteric, Peritoneal, and Round Ligament Hydatid Cysts—A Rare Report of a Case and a Systematic Literature Review
Previous Article in Special Issue
Pedicled Rectus Femoris Flap for Restoration of Suprapatellar Quadriceps Tendon and Defect Coverage after Multiple Reconstruction Attempts—A Case Report and Literature Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 14
Issue 2
10.3390/jpm14020206
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Exploring an Innovative Approach: Integrating Negative-Pressure Wound Therapy with Silver Nanoparticle Dressings in Skin Graft Procedures

by
Abdalah Abu-Baker
1,2,
Andrada-Elena Țigăran
2,
Teodora Peligrad
2,
Daniela-Elena Ion
2,
Daniela-Elena Gheoca-Mutu
2,3,*,
Adelaida Avino
1,2,
Cristian-Sorin Hariga
4,5,
Oriana Elena Moraru
6,7,
Laura Răducu
2,5,* and
Radu-Cristian Jecan
2,5
1
Doctoral School, “Carol Davila” University of Medicine and Pharmacy, 010221 Bucharest, Romania
2
Department of Plastic Surgery, “Prof. Dr. Agrippa Ionescu” Emergency Clinical Hospital, 011356 Bucharest, Romania
3
Discipline of Anatomy, “Carol Davila” University of Medicine and Pharmacy, 010221 Bucharest, Romania
4
Department of Plastic Surgery, Emergency Clinical Hospital, 014461 Bucharest, Romania
5
Discipline of Plastic Surgery, “Carol Davila” University of Medicine and Pharmacy, 010221 Bucharest, Romania
6
Discipline of Cardiovascular Surgery, “Carol Davila” University of Medicine and Pharmacy, 010221 Bucharest, Romania
7
Department of Vascular Surgery, “Prof. Dr. Agrippa Ionescu” Emergency Clinical Hospital, 011356 Bucharest, Romania
*
Authors to whom correspondence should be addressed.
J. Pers. Med. 2024, 14(2), 206; https://doi.org/10.3390/jpm14020206
Submission received: 12 January 2024 / Revised: 4 February 2024 / Accepted: 9 February 2024 / Published: 14 February 2024
(This article belongs to the Special Issue Implications for Personalized Plastic, Aesthetic and Reconstructive Surgery)
Browse Figures
Versions Notes

Abstract

:
Background: Skin grafting is a helpful instrument in a plastic surgeon’s arsenal. Several types of dressings were designed to facilitate the process of graft integration. Negative-pressure wound therapy is a proven dressing method, enhancing graft survival through several mechanisms: aspiration of secretions, stimulation of neoangiogenesis, and promotion of an anti-inflammatory environment. Silver nanoparticle dressings also bring multiple benefits by bearing an antimicrobial effect and providing a humid medium, which are favorable for epithelialization. The combination of NPWT (negative-pressure wound therapy) with AgNPs (silver nanoparticles) has not been widely studied. Materials and methods: This study aimed to compare the outcomes of silver nanoparticle sheets with the combination of negative-pressure wound therapy and silver nanoparticle dressings. We conducted a comparative prospective study on 80 patients admitted to the Plastic Surgery Department of “Prof. Dr. Agrippa Ionescu” Emergency Clinical Hospital between 1st of January 2020 and 31st of December 2022. The study population was randomized to receive either silver nanoparticle dressings or negative-pressure wound therapy (NPWT) combined with silver nanoparticle dressings. Various parameters were monitored, including patient comorbidities and graft-related data such as defect etiology, graft integration, and graft size. Dressings were changed, and graft status was evaluated at 7, 10, and 14 days postoperatively. Additionally, baseline C-reactive protein (CRP) levels were measured before surgery and 7, 10, and 14 days postoperatively. Results: The study demonstrated an enhanced integration of skin grafts at all evaluation stages when employing NPWT combined with AgNPs, particularly evident 10 days post operation. Significant variations in graft integration were also observed based on factors such as diabetes, cardiovascular disease, graft size, or the origin of the grafted defect. Moreover, dynamic C-reactive protein monitoring showed a statistically significant decrease in CRP levels 10 days post operation among patients treated with NPWT in conjunction with silver dressing, consistent with the nearly complete integration of skin grafts at this evaluation threshold. Conclusion: Several factors influence the postoperative evolution of split-skin grafts. Postoperative dressings target local factors to enhance graft integration further. Our research demonstrated that the innovative combination of NPWT-assisted dressings, complemented by a silver nanoparticle sheet, resulted in improved benefits for graft integration and the alleviation of systemic inflammation.

1. Introduction

An essential and valuable tool in a plastic surgeon’s reconstructive toolkit is skin grafting. It provides a quick and straightforward method to cover a variety of defects, including burns, chronic skin ulcers, and post-excisional soft-tissue defects, which would typically require a longer period to heal through secondary epithelialization [1]. Skin grafting involves the excision of an area of epidermis with a variable amount of the underlying dermis, applied to an open wound [2].
Grafts generally integrate well into healthy wound beds. However, several postoperative circumstances have a significant impact on integration. For instance, the presence of fluid between the wound bed and the graft can lead to graft separation and hinder the establishment of new blood supply [3]. Hemostasis must, therefore, be carefully performed during surgery to avoid hematomas. Seromas underneath the graft are better tolerated than hematomas but can lead to graft necrosis nonetheless [4]. A practical solution to fluid build-up involves creating tiny pores in the graft surface to facilitate drainage [5]. Infection is another factor that impedes graft integration, evident through local and systemic inflammatory responses. Graft movement in relation to the bed may also result in a lack of graft integration because the freshly generated capillaries are unable to inosculate the graft [6].
To counteract these undesirable events, various types of dressings were designed [7]. These dressings aimed to mitigate fluid build-up and prevent graft movement by compressing the graft onto the wound bed while also inhibiting bacterial proliferation [8]. Additionally, some of these dressings can modulate the local wound environment at the molecular level, favoring healing-prone conditions, which, in turn, lead to an improved graft take.
Negative-pressure wound therapy (NPWT) stands as a revolutionary tool in plastic surgery, offering extensive benefits for wound healing. NPWT is utilized to treat various disorders, including acute wounds, posttraumatic deformities, chronic ulcers, and skin grafts [9]. The mechanism typically involves placing a sterile sponge directly on top of the wound, covered with an impermeable sheet, to create a hermetically sealed area. Subsequently, a negative pressure pump is connected to the newly created compartment, subjecting the dressed area to a vacuum [10].
Multiple publications support the role of NPWT in wound healing. Usually, we can find an overexpression of TNFα (tumor necrosis factor α), interleukin-1, and interleukin-6 in chronic wounds, originating from hyperglycemia and persistent wound inflammation. High concentrations of such cytokines promote a proinflammatory milieu that inhibits angiogenesis and proper wound healing [11]. NPWT application produces a substantial decrease in early local tumor necrosis factor (TNF) and interleukin (IL) 1 expression for both chronic and acute wounds [12,13]. As well as for diabetic wounds, NPWT was found to be effective in suppressing the IL-6 expression, therefore enhancing the healing process [14,15].
Potent proangiogenic and chemokine IL-8 is also involved in controlling neutrophil and macrophage migration, thus hastening wound healing [16,17]. The application of NPWT resulted in a significant increase in local IL-8 expression in a study involving human wounds [15]. Within four hours of applying NPWT, there was a notable increase in systemic levels of the anti-inflammatory cytokine IL-10 [14].
Another revolutionary tool is silver nanoparticle dressings. Silver nanoparticles exert a significant antimicrobial effect upon contact with tissues. In its metallic state, silver is inert and lacks biocidal properties. However, in the presence of water or tissue fluids, it ionizes, releasing Ag+ or other physiologically active ions. This “activated” ion has a high affinity for sulphydryl groups and protein residues on cell membranes [18]. Importantly, silver exhibits antibacterial activity even at concentrations that are as low as 1 ppm. Silver particles accumulate in sensitive microorganisms against a concentration gradient, ultimately leading to cellular death [19].
AgNPs (silver nanoparticles) also influence factors related to both growth and inflammation. AgNP dressings were shown to produce a significantly higher concentration of VEGF (vascular endothelial growth factor). These dressings can also increase the level of other growth factors, such as TGF-β1(transforming growth factor β1) and bFGF (fibroblast growth factor), as well as reduce the levels of pro-inflammatory markers such as TNF-α and IL-1β. Due to their effect on the inflammatory response, AgNPs are considered highly beneficial in the wound healing process [20].
While the literature has extensively discussed the advantages of using NPWT and silver dressings separately, there is limited information available on their combined usage in the management of skin grafts. This study aimed to demonstrate that the combination of silver dressings with NPWT offers a beneficial approach to managing lower-extremity grafts.

2. Materials and Methods

This study aimed to compare the effects of tie-over silver nanoparticle dressings and NPWT used in combination with the AgNP dressings on graft integration. We conducted a clinical observational prospective study involving 80 patients hospitalized in the Plastic Surgery Department of “Prof. Dr. Agrippa Ionescu” Emergency Clinical Hospital between 1st of January 2020 and 31st of December 2022 with lower-limb-skin and soft-tissue defects. Informed consent was obtained from all subjects involved in the study.

2.1. Inclusion Criteria

  • Patients with lower-limb soft-tissue defects that required grafting;
  • Adults.

2.2. Exclusion Criteria

  • Children;
  • Pregnant women;
  • Patients who refused to participate;
  • Patients discharged earlier than 14 days;
  • Active infections.

2.3. Variables and Definitions

The data collected included patient-dependent variables, such as sex, age, cardiovascular and diabetic comorbidities, as well as graft-related factors: percentage of graft take 7, 10, and 14 days post operation, graft size, and defect origin. Grafted defects were acquired either through ulceration debridement or excision of a soft tissue mass.
Graft status was assessed through a clinical evaluation of integration signs, including color, graft aspect, level and quality of exudate, and visualization of epithelium between the graft net branches. We calculated the percentage of graft integration by dividing the viable graft area by the total surface of the graft.
The graft area was measured in cm2. The cohort was then divided based on graft area in three categories:
  • Graft area smaller than 150 cm2–25 patients;
  • Graft area between 150 cm2 and 500 cm2–42 patients;
  • Graft area greater than 500 cm2–13 patients.
We also measured C-reactive protein (CRP) levels before surgery and 7, 10, and 14 days post operation. Thus, we were able to evaluate the CRP levels dynamically and compare their evolution depending on the type of dressing used.
The study population was randomized to receive either of the proposed dressing methods.
Out of 80 patients, 41 were treated with silver nanoparticle compressive dressings. This dressing consisted of an AgNP sheet placed over the graft and secured with a tie-over bolster, providing pressure and preventing graft movement. The dressing was changed 7, 10, and 14 days post operation for local lavage and to assess graft status.
The other 39 patients benefited from NPWT aided by silver nanoparticle dressing. The first layer consisted of an AgNP dressing directly applied to the skin graft. The second layer comprised the NPWT dressing connected to the vacuum machine. The negative-pressure pump operated on an alternating regime of 125 mmHg for 3 min, followed by 75 mmHg for another 3 min. The NPWT dressing was changed 7, 10, and 14 days post operation, and the graft status was assessed. Figure 1 illustrates the dressing and assessment schedule.

2.4. Statistical analysis

Data collection was performed using Microsoft Office Excel 2010. We performed statistical analysis using SPSS version 26.0 software (IBM Corporation, Armonk, NY, USA), all taking into consideration a 95% confidence interval. Text editing was performed using Microsoft Office Word 2010.

3. Results

The study population comprised 44 males and 36 females, with a mean age of 64 years. Among the participants, 58 had cardiovascular comorbidities, and 61 had type 2 diabetes mellitus. Regarding the origin of the defects, 28 resulted from the excision of soft-tissue tumors, while the remaining 52 followed chronic ulcer debridement. The cohort included 25 patients with small grafts (<150 cm2), 42 patients with medium-sized grafts (150–500 cm2), and 13 patients with large grafts (>500 cm2). The distribution of the subjects into the two study lots is illustrated in Table 1.
Comparing the two methods of graft dressing on the 7, 10, and 14 days post operation, we observed a higher graft integration in patients who received the combination of NPWT and AgNP-impregnated sheets. The average graft take at the 7th day for grafts dressed with only a silver layer was 74.88%, compared to 85% for those treated with NPWT and AgNP dressing. On the other hand, at the 10-day threshold, a significant difference was observed between the two means, with a graft take of 87.20% for silver nanoparticle sheets and 97.56% for vacuum-assisted dressings combined with AgNPs. This difference persisted until 14 days post operation, with a mean integration of 93.41% for silver-dressed grafts and 99.62% for grafts treated with NPWT and AgNPs. We can observe a better result in graft integration for the NPWT+AgNP lot, especially at the 7- and 10-day thresholds. All these differences were statistically evaluated using the independent T-test, which showed a high degree of statistical significance (p < 0.001). The statistical data are also displayed in Table 2.
We assessed the graft evolution separately depending on the presence of cardiovascular disease. We evaluated the effect size of applying NPWT+AgNPs using the Cohen D formula. The data obtained are available in Table 3. Our observations reveal that the combination of NPWT and silver nanoparticle dressings resulted in improved graft integration at every evaluation threshold, showing a statistically significant difference for patients with cardiovascular disease (p < 0.001). The data also indicate a strong effect size at every threshold for patients with cardiovascular comorbidities (D < −0.8), with the most substantial difference observed one week after grafting.
Regarding the presence of diabetes mellitus, we observed an improvement in graft integration with the use of NPWT+AgNPs. The independent T-test showed a statistically significant difference in graft take when adding NPWT to the dressing (p < 0.001) for diabetic patients. We also observed a strong effect size (D < −1) for diabetic patients at all stages. Data is presented in Table 4.
Depending on graft area, we separated the patients into three categories. We observed that the NPWT+AgNP dressings resulted in higher graft integration rates for every category compared to simple silver nanoparticle dressings. Moreover, this improvement was statistically significant for medium and large grafts (p < 0.01), as illustrated in Table 5.
Taking into consideration the effect size of NPWT+AgNPs, we observed a varied D coefficient for small grafts (ranging from −0.46041 to −0.77274), a strong D coefficient (D < −0.8) for medium graft, and an even stronger D coefficient for large grafts. These data show that the benefit of choosing NPWT+AgNPs is far greater for grafts of a larger area compared to smaller grafts.
The defect etiology, whether resulting from the excision of a soft-tissue tumor or the debridement of an ulceration, may influence the integration process of the graft. Post-excisional defects typically represent clean surgical wounds, whereas debrided ulcerations may still carry inflammatory and infectious repercussions specific to chronic wounds.
The data analysis showed, once again, an improvement in graft integration for patients treated with NPWT+AgNPs. According to our study, this progress was statistically significant (p < 0.001) at the 7- and 10-day thresholds. The effect size generally showed a strong benefit resulting from using silver dressings aided by NPWT, even if there was no clear distinction between the two categories. Statistical data analysis is shown in Table 6.
The measurements of the C-reactive protein showed similar starting points before grafting. At the 7-day evaluation, a small difference was observed between the two lots, with an average of 36.97 mg/dL for the NPWT+AgNPs group compared to 38.02 mg/dL for the patients with silver dressings. However, the difference was not statistically significant. A considerable decrease in the CRP level for patients who received NPWT+AgNP dressings was observed on day 10 after grafting, with a level of 7267 mg/dL, compared to 11,473 mg/dL for the other lot, as demonstrated in Table 7. Dynamic monitoring illustrated a tendency towards the normalization of CRP levels 14 days post operation, with the difference between the two groups decreasing (3338 mg/dL for patients dressed with NPWT+AgNPs compared to 4129 mg/dL for the group dressed with a silver sheet). It should be noted that the CRP values 14 days after the grafting were close to the baseline values measured before the surgical intervention. From this point of view, only the patients belonging to the group dressed with NPWT aided by silver nanoparticle sheets had lower CRP serum levels than the post-operation levels. We performed the statistical analysis of the data related to the C-reactive protein level and noted a statistically significant difference at the 10-day evaluation, p = 0.001. The dynamic variation of CRP levels is also displayed in Figure 2.

4. Discussion

As expected, NPWT systems confer a considerable benefit for skin graft integration, directly addressing most of the possible causes of failure, while enhancing graft revascularization. Compared to conventional skin graft dressings, NPWT was superior in most aspects, with higher graft integration rates, especially at the earlier evaluation checkpoints.
Negative pressure creates multiple benefits for skin graft integration, such as removing excess fluid build-up from the wound bed and contracting the wound edges by a mechanical force [21]. Additionally, the negative pressure generated by the vacuum exerts effects at the molecular level, inhibiting proinflammatory chemokines and promoting the secretion of anti-inflammatory and angiogenic growth factors, such as interleukin-10 and vascular endothelial growth factor [22]. Thus, NPWT is responsible for creating a healing-prone medium supporting neo-angiogenesis and epithelialization [23]. Another advantage of vacuum devices is minimizing the bacterial population of an infected wound [24]. Moreover, vacuum-assisted dressings ensure a lack of movement between the graft and the wound bed by applying pressure evenly on all sides of the wound [25]. These effects can be achieved while the patients maintain a certain degree of mobility, consequently decreasing the risk of eschars or deep vein thrombosis associated with prolonged bed stay [26].
Moreover, multiple publications have investigated the variation of the vascular endothelial growth factor (VEGF) in connection to NPWT [27,28,29]. When NPWT was applied, local VEGF expression significantly increased in both chronic and acute (traumatic) wounds. A concentration gradient was described by Erba and colleagues, with the tissue near the wound surface, alongside the graft, expressing the highest level [30]. Better vascularization and improved wound healing were the outcomes of the NPWT group’s gradient of expression.
Fibroblast growth factor (FGF) 2 (b-FGF), a powerful mitogen that induces an angiogenic phenotype, was also studied in the setting of NPWT application [31]. A total of 48 h after NPWT treatment, a higher FGF-2 expression was observed in murine fibroblast models, assisting in processes such as neovascularization and fibrosis [32].
Furthermore, dressings impregnated with silver nanoparticles are efficient instruments to prevent wound infection. The mechanisms of silver’s antibacterial effect on sensitive species are diverse. This process starts with silver binding to cell membranes, leading to intracellular absorption by endocytic vacuoles and phagocytosis [33]. The inactivation of membrane-related enzymes causes the denaturation of the bacterial cell envelope and its functional capacity to regulate the inward diffusion of nutrients [34]. Membrane damage, shown as pitting and increased permeability, has been recognized as a precursor to lethality. The potential of silver to disrupt essential intracellular enzyme systems by affecting trace metals and electrolytes likely accounts for most of its intracellular effects. The accumulated damage leads to deficient respiratory pathways and RNA and DNA replication, resulting in bacterial death. Moreover, silver nanoparticles seem to also have a role in countering antibiotic resistance. These effects can be visible even from small concentrations of silver ions, as low as 1 ppm [35].
In addition, the research indicates that dressings infused with silver nanoparticles promote wound healing [36]. They are known to hasten wound closure by interacting with keratinocytes and fibroblasts, causing wound contraction and healing. Silver particles have also been shown to modulate cytokine levels by inhibiting neutrophils and decreasing the quantity of reactive oxygen species [37].
Regarding the cellular influence and macrophage immunomodulation produced by ionic silver (Ag+), Varela et al. reported that there was an impressive increase in TGF-cytokine secretion after interaction with silver-containing dressings [38]. Hesketh et al. reported that ionic silver molecules trigger macrophage immunomodulation toward the M2-state, potentially M2a or M2c, two pro-angiogenic subtypes with important roles in wound healing. TGF secretion, which has profibrotic properties and is linked with the M2a and M2c subsets of M2 macrophages, is also significantly increased by silver-containing dressings [39]. Additionally, in the presence of silver-containing materials, macrophages consume slightly less glucose, demonstrating that these macrophages are polarizing on a continuous spectrum toward M2-macrophages, as an increased expression of glucose transporters (primarily GLUT1) on the membrane and higher rates of glucose consumption have been associated with pro-inflammatory M1 macrophages [40].
Given the fact that AgNPs can help eliminate bacteria and convert macrophages into a wound-healing population, they are a viable treatment for chronic wounds, with positive effects on inflammatory response inhibition and proper cicatrization [41].
Overall, the combination of NPWT and silver nanoparticle sheets proves a synergistic and beneficial effect on wound healing and graft integration. As Khansa et al. reported, infected diabetic foot ulcers were proven to heal more quickly with the use of silver-coated sponges instead of plain ones, as they reduce the bacterial growth of biofilm-causing species (Pseudomonas aeruginosa and Staphylococcus aureus, even MRSA) [42,43]. The synergistic effects of silver and NPWT can be achieved by applying a silver layer underneath a standard polyurethane sponge or by utilizing a polyurethane sponge coated with silver [44].
Moreover, in the study conducted by Hanh et al., according to the tissue culture findings, a significantly lower rate of bacterial growth was noted in the group of patients that received NPWT+silver dressings, compared to the control group. The much lower incidence of bacterial colonization further supports the effectiveness of the inclusion of AgNP-coated dressings in NPWT systems [45]. The study showed better outcomes in terms of infection when using silver-impregnated NPWT, compared to the standard one [46].
As highlighted by Sapino et al. in their comparative study, there was a difference in graft integration between VAC patients and non-VAC patients, with rates of 92% compared to 72% [47]. Mo et al. observed a slightly lower difference in graft outcome: 86.7% integration for NPWT-treated patients, compared to 74.1% for those with tie-over bolsters [48]. In our study, we observed a 99.62% graft integration at the 14-day threshold postoperatively for patients benefiting from the NPWT-Ag+ combination, compared to 93.41% for patients treated with silver nanoparticle dressings alone. Therefore, we observed that an improvement in graft take resulted from the use of silver nanoparticle sheet in conjunction with NPWT. Another study conducted by Blume et al. showed a significant difference in graft outcome at the 5-day threshold postoperatively, with values of 97% for NPWT-treated patients, compared to 84% for conventional therapy groups [49]. This further reinforces the hypothesis that NPWT contributes to enhanced early graft integration, as highlighted by our results.
Patients with diabetes mellitus present with multiple alterations of peripheral homeostasis, such as improper blood supply, caused by microangiopathy and vegetative neuropathy, and predisposition to chronic ulcer infection, often with resistant microorganisms [50,51,52]. A study conducted by Wu et al. compared graft integration rates in diabetic patients, showing a skin graft survival rate of 100% for the NPWT-treated group, contrasting with 76% for those healed with conventional moist dressings [53]. Another study by Bordianu et al. showed complete graft integration for 56 out of 63 cases of grafted diabetic foot ulcerations with the use of NPWT [54]. Furthermore, Ramanujam et al. demonstrated an increased healing time for diabetic patients (5.74 weeks compared to 3.75 weeks) [7]. Our data suggest that there is a benefit in using NPWT+AgNPs for diabetic patients, with an integration rate of 99.67% at 2 weeks compared to 91.29% for the other lot, and a stronger effect size of −1.23 for diabetic patients compared to 0.48 for nondiabetics.
Congestive heart failure and other cardiovascular comorbidities may also influence the process of graft take. Turissini et al. demonstrated a higher probability of skin graft failure in patients suffering from congestive heart failure [55]. On the other hand, Lim et al. established that 19 out of 41 patients suffering from ischemic heart disease achieved complete wound healing under NPWT [56]. Our data also suggest that the combination of NPWT and silver nanoparticle dressings improved skin graft integration in all patients, with an integration rate of 99.29% for patients without heart disease and 99.8% for patients with heart disease (compared to 93.75%, respectively 93.33% for patients treated with silver dressings).
Smaller grafts generally adhere better to the wound bed, while larger grafts are more prone to decreased graft integration and local complications, as stated by Zhao et al. [57]. Another study by Liao et al. showed higher integration rates for smaller grafts (92% vs. 82%) [58]. Furthermore, Nakamura et al. compared grafts of similar medium sizes (mean of 391.2 cm2 for tie-over and 254.6 cm2 for NPWT), and they found an improvement in graft take for those treated with NPWT [59]. Our data align with this hypothesis, showing better results for smaller grafts, ranging from 100% and 98.57% for those treated with NPWT+AgNPs and silver dressings, respectively, to 99.38 and 80% for large grafts managed likewise. It is also significant to underline the higher effect size of NPWT when used on larger grafts.
From a pathophysiological standpoint, leg ulcerations are characterized by increased leukocyte infiltration and endothelial cell permeability, as well as elevations in inflammatory cytokines, matrix metalloproteinases (MMPs), reactive oxygen and nitrogen species, iron deposition, and tissue metabolites [60]. A study investigating the use of NPWT after lower limb ulceration debridement reported improvement in graft adherence compared to conventional dressing (99.2% for NPWT and 89.7% for conventional dressing) [61]. Moreover, Kantak et al. stated that NPWT also showed its benefits in burn patients, with a median graft integration of 97% [62]. Our analyzed data suggest a similar phenomenon, with higher graft takes for acute surgical wounds compared to chronic ulcerations. Nevertheless, the combination of NPWT+AgNPs seems to offer a greater benefit in the case of debrided ulcerations.
CRP is an acute response protein, mainly produced in the liver, although it may originate from other tissues in certain conditions. The CRP content in the blood rises sharply from 0.8 mg/L to 600–1000 mg/L during the acute-phase response to inflammation, peaking after around 48 h. CRP has a half-life of around 19 h, and once the trigger for the enhanced production stops, the concentration in the blood quickly recovers to baseline levels [63]. High CRP readings more accurately represent inflammation and/or tissue damage than other markers such as plasma viscosity and erythrocyte sedimentation rate, even if there is no apparent association between the two and the severity of the disease [64]. A study by Legendre et al. compared the CRP blood levels of 41 individuals with chronic venous leg ulcers with those of a control group without ulcers and demonstrated a positive correlation between CRP and wound healing. Individuals who experienced various wound problems (for example, an infection) had CRP levels that were, on average, greater (~35 mg/L) than those participants who did not experience any issues (~9 mg/L). It was believed that a concentration greater than 15 mg/mL indicates wound inflammation [65].
A study by Rashid et al. demonstrated a decrease in C reactive protein levels after applying NPWT (78% of patients) [66]. Another study by Liu et al. showed declining CRP levels from 66.4 mg/l to 10.4 mg/l after a mean NPWT application time of 13 days [67]. Accordingly, our data suggest a decrease in CRP levels after NPWT treatment, with an accentuated drop at the 10-day threshold, in line with an accelerated graft integration observed for patients that benefitted from the combination of NPWT and silver nanoparticle dressings.
The strengths of this study are represented by the innovative combination of NPWT dressings with silver nanoparticle dressings, mutually enhancing their antimicrobial and anti-inflammatory effects, and showing great results in promoting graft integration for both acute and chronic wounds. Furthermore, we present an improved management approach to chronic ulcers larger than 150 cm2. Taking into consideration that there is no other viable reconstruction method for this pathology, our proposal is cost-efficient and helps decrease the burden on the medical care system. Consequently, we are currently developing a prospective study focusing on the quality of life of patients with this condition. Subsequently, our goal is to update the protocols currently in use for the treatment of skin ulcers. However, it is important to note that this study faced limitations due to pandemic restrictions, resulting in fewer cases during the selected period and a decrease in the accessibility of patients to public health institutions. Another limitation of this study is the absence of blinding.
In order to better visualize the graft integration using the studied dressing methods, we have included photos depicting the process of graft healing (Figure 3, Figure 4, Figure 5 and Figure 6).

5. Conclusions

Many factors influence the postoperative evolution of a split-skin graft, from general factors such as patient status and comorbidities to local factors such as mechanical shearing forces, lifting of the graft from the wound bed, or infection. Postoperative dressings address local factors to further increase graft integration.
The results of our study pointed out improvements in the treatment and care of grafted patients using NPWT combined with a silver nanoparticle sheet compared to silver nanoparticle dressings secured with tie-over bolsters. The most notable benefits of this novel dressing method are better graft integration as well as decreased levels of systemic inflammatory markers.

Author Contributions

Conceptualization, L.R.; methodology, A.A.-B.; software, A.-E.Ț.; validation, A.A., D.-E.G.-M. and T.P.; formal analysis, L.R.; investigation, A.A.-B.; resources, A.A.-B., D.-E.I. and C.-S.H.; data curation, A.-E.Ț. and O.E.M.; writing—original draft preparation, A.A.-B.; writing—review and editing, A.A., D.-E.G.-M. and L.R.; visualization, A.A., D.-E.G.-M. and L.R.; supervision, L.R. and R.-C.J.; project administration, L.R. and R.-C.J. All authors have read and agreed to the published version of the manuscript.

Funding

Publication of this paper was supported by the University of Medicine and Pharmacy Carol Davila, through the institutional program “Publish not Perish”.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of “Professor Dr Agrippa Ionescu” Clinical Emergency Hospital (protocol no. 226367/25.07.2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors on request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Herskovitz, I.; Hughes, O.B.; Macquhae, F.; Rakosi, A.; Kirsner, R. Epidermal skin grafting. Int. Wound J. 2016, 13, 52–56. [Google Scholar] [CrossRef]
  2. Sun, B.K.; Siprashvili, Z.; Khavari, P.A. Advances in skin grafting and treatment of cutaneous wounds. Science 2014, 346, 941–945. [Google Scholar] [CrossRef]
  3. Khan, A.A.; Khan, I.M.; Nguyen, P.P.; Lo, E.; Chahadeh, H.; Cerniglia, M.; Noriega, J.A. Skin Graft Techniques. Clin. Podiatr. Med. Surg. 2020, 37, 821–835. [Google Scholar] [CrossRef] [PubMed]
  4. Jarjis, R.D.; Jørgensen, L.; Finnerup, K.; Birk-Sørensen, L. Complications in skin grafts when continuing antithrombotic therapy prior to cutaneous surgery requiring skin grafting: A systematic review. J. Plast. Surg. Hand Surg. 2015, 49, 129–134. [Google Scholar] [CrossRef]
  5. Paw, E.; Vangaveti, V.; Zonta, M.; Heal, C.; Gunnarsson, R. Effectiveness of fibrin glue in skin graft survival: A systematic review and meta-analysis. Ann. Med. Surg. 2020, 56, 48–55. [Google Scholar] [CrossRef]
  6. Louiselle, A.E.; Niemiec, S.M.; Zgheib, C.; Liechty, K.W. Macrophage polarization and diabetic wound healing. Transl. Res. 2021, 236, 109–116. [Google Scholar] [CrossRef] [PubMed]
  7. Ramanujam, C.L.; Han, D.; Fowler, S.; Kilpadi, K.; Zgonis, T. Impact of Diabetes and Comorbidities on Split-Thickness Skin Grafts for Foot Wounds. J. Am. Podiatr. Med. Assoc. 2013, 103, 223–232. [Google Scholar] [CrossRef]
  8. Patel, B.J.; Asher, C.M.; Bystrzonowski, N.; Healy, C. Safeguarding Skin Grafts: An Evidence-Based Summary of Fixation Techniques. Ann. Plast. Surg. 2021, 87, e180–e188. [Google Scholar] [CrossRef]
  9. Rădulescu, M.; Andronescu, E.; Cirja, A.; Holban, A.M.; Mogoantă, L.; Bălşeanu, T.A.; Cătălin, B.; Neagu, T.P.; Lascăr, I.; Florea, D.A.; et al. Antimicrobial coatings based on zinc oxide and orange oil for improved bioactive wound dressings and other applications. Rom. J. Morphol. Embryol. 2016, 57, 107–114. [Google Scholar] [PubMed]
  10. Avino, A.; Jecan, C.R.; Cozma, C.N.; Balcangiu Stroescu, A.E.; Balan, D.G.; Ionescu, D.; Mihai, A.; Tanase, M.; Raducu, L. Negative Pressure Wound Therapy Using Polyurethane Foam in a Patient with Necrotizing Fasciitis. Mater. Plast. 2018, 55, 603–605. [Google Scholar] [CrossRef]
  11. Ravindhran, B.; Schafer, N.; Howitt, A.; Carradice, D.; Smith, G.; Chetter, I. Molecular mechanisms of action of negative pressure wound therapy: A systematic review. Expert Rev. Mol. Med. 2023, 25, e29. [Google Scholar] [CrossRef]
  12. Yamashiro, T.; Kushibiki, T.; Mayumi, Y.; Tsuchiya, M.; Ishihara, M.; Azuma, R. Negative-Pressure Wound Therapy: What We Know and What We Need to Know. Adv. Exp. Med. Biol. 2023, 1436, 131–152. [Google Scholar] [CrossRef]
  13. Normandin, S.; Safran, T.; Winocour, S.; Chu, C.K.; Vorstenbosch, J.; Murphy, A.M.; Davison, P.G. Negative Pressure Wound Therapy: Mechanism of Action and Clinical Applications. Semin. Plast. Surg. 2021, 35, 164–170. [Google Scholar] [CrossRef]
  14. Nolff, M.C. Filling the vacuum: Role of negative pressure wound therapy in open wound management in cats. J. Feline Med. Surg. 2021, 23, 823–833. [Google Scholar] [CrossRef]
  15. Song, H.; Xu, Y.; Chang, W.; Zhuang, J.; Wu, X. Negative pressure wound therapy promotes wound healing by suppressing macrophage inflammation in diabetic ulcers. Regen. Med. 2020, 15, 2341–2349. [Google Scholar] [CrossRef]
  16. Kutwin, M.; Woźniacka, A. Interleukins 20 and 8—Less widely known cytokines in psoriasis. Adv. Dermatol. Allergol. 2023, 40, 194–203. [Google Scholar] [CrossRef] [PubMed]
  17. Hu, Y.-J.; Song, C.-S.; Jiang, N. Single nucleotide variations in the development of diabetic foot ulcer: A narrative review. World J. Diabetes 2022, 13, 1140–1153. [Google Scholar] [CrossRef] [PubMed]
  18. Ongarora, B.G. Recent technological advances in the management of chronic wounds: A literature review. Heal. Sci. Rep. 2022, 5, e641. [Google Scholar] [CrossRef]
  19. Fol, M.F.; Hamdi, S.A.-H.; Abdel-Rahman, H.A.; Mostafa, N.A. In vivo efficacy of silver nanoparticles against Syphacia muris infected laboratory Wistar rats. J. Parasit. Dis. 2023, 47, 744–756. [Google Scholar] [CrossRef] [PubMed]
  20. Li, R.; Xu, Z.; Jiang, Q.; Zheng, Y.; Chen, Z.; Chen, X. Characterization and biological evaluation of a novel silver nanoparticle-loaded collagen-chitosan dressing. Regen. Biomater. 2020, 7, 371–380. [Google Scholar] [CrossRef] [PubMed]
  21. Sabarees, G.; Velmurugan, V.; Tamilarasi, G.P.; Alagarsamy, V.; Solomon, V.R. Recent Advances in Silver Nanoparticles Containing Nanofibers for Chronic Wound Management. Polymers 2022, 14, 3994. [Google Scholar] [CrossRef] [PubMed]
  22. Yin, Y.; Zhang, R.; Li, S.; Guo, J.; Hou, Z.; Zhang, Y. Negative-pressure therapy versus conventional therapy on split-thickness skin graft: A systematic review and meta-analysis. Int. J. Surg. 2018, 50, 43–48. [Google Scholar] [CrossRef]
  23. Glass, G.E.; Murphy, G.F.; Esmaeili, A.; Lai, L.; Nanchahal, J. Systematic review of molecular mechanism of action of negative-pressure wound therapy. Br. J. Surg. 2014, 101, 1627–1636. [Google Scholar] [CrossRef]
  24. Wu, M.M.; Liu, Q.; Yu, Z.M.; Karvar, M.; Aoki, S.M.; Hamaguchi, R.B.; Ma, C.; Orgill, D.P.M.; Panayi, A.C. Negative-Pressure Wound Therapy Induces Lymphangiogenesis in Murine Diabetic Wound Healing. Plast. Reconstr. Surg. 2023, 151, 779–790. [Google Scholar] [CrossRef] [PubMed]
  25. Liu, Z.; Dumville, J.C.; Hinchliffe, R.J.; Cullum, N.; Game, F.; Stubbs, N.; Sweeting, M.; Peinemann, F. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. Cochrane Database Syst. Rev. 2018, 2018, CD010318. [Google Scholar] [CrossRef] [PubMed]
  26. Cuomo, R.; Grimaldi, L.; Nisi, G.; Zerini, I.; Giardino, F.R.; Brandi, C. Ultraportable Devices for Negative Pressure Wound Therapy: First Comparative Analysis. J. Investig. Surg. 2021, 34, 335–343. [Google Scholar] [CrossRef] [PubMed]
  27. Shou, K.; Niu, Y.; Zheng, X.; Ma, Z.; Jian, C.; Qi, B.; Hu, X.; Yu, A. Enhancement of Bone-Marrow-Derived Mesenchymal Stem Cell Angiogenic Capacity by NPWT for a Combinatorial Therapy to Promote Wound Healing with Large Defect. BioMed Res. Int. 2017, 2017, 7920265. [Google Scholar] [CrossRef]
  28. Shah, A.; Sumpio, B.J.; Tsay, C.; Swallow, M.; Dash, B.; Thorn, S.L.; Sinusas, A.J.; Koo, A.; Hsia, H.C.; Au, A. Incisional Negative Pressure Wound Therapy Augments Perfusion and Improves Wound Healing in a Swine Model Pilot Study. Ann. Plast. Surg. 2019, 82, S222–S227. [Google Scholar] [CrossRef]
  29. Notorgiacomo, G.; Klug, J.; Rapp, S.; Boyce, S.T.; Schutte, S.C. A bioreactor for studying negative pressure wound therapy on skin grafts. Int. Wound J. 2022, 19, 633–642. [Google Scholar] [CrossRef]
  30. Erba, P.; Ogawa, R.; Ackermann, M.; Adini, A.; Miele, L.F.; Dastouri, P.; Helm, D.; Mentzer, S.J.; D’amato, R.J.; Murphy, G.F.; et al. Angiogenesis in Wounds Treated by Microdeformational Wound Therapy. Ann. Surg. 2011, 253, 402–409. [Google Scholar] [CrossRef]
  31. Wang, X.; Fan, W.; Li, N.; Ma, Y.; Yao, M.; Wang, G.; He, S.; Li, W.; Tan, J.; Lu, Q.; et al. YY1 lactylation in microglia promotes angiogenesis through transcription activation-mediated upregulation of FGF2. Genome Biol. 2023, 24, 87. [Google Scholar] [CrossRef] [PubMed]
  32. Mascharak, S.; Desjardins-Park, H.E.; Davitt, M.F.; Guardino, N.J.; Gurtner, G.C.; Wan, D.C.; Longaker, M.T. Modulating Cellular Responses to Mechanical Forces to Promote Wound Regeneration. Adv. Wound Care 2022, 11, 479–495. [Google Scholar] [CrossRef] [PubMed]
  33. Burlec, A.F.; Corciova, A.; Boev, M.; Batir-Marin, D.; Mircea, C.; Cioanca, O.; Danila, G.; Danila, M.; Bucur, A.F.; Hancianu, M. Current Overview of Metal Nanoparticles’ Synthesis, Characterization, and Biomedical Applications, with a Focus on Silver and Gold Nanoparticles. Pharmaceuticals 2023, 16, 1410. [Google Scholar] [CrossRef] [PubMed]
  34. Avino, A.; Marina, C.; Balcangiu-Stroescu, A.E.; Tanasescu, M.D.; Balan, D.G.; Timofte, D.; Stoicescu, S.; Hariga, C.S.; Ionescu, D. Our Expe-rience in Skin Grafting and Silver Dressing for Venous Leg Ulcers. Rev. Chim. 2019, 70, 742–744. [Google Scholar] [CrossRef]
  35. Kaiser, K.G.; Delattre, V.; Frost, V.J.; Buck, G.W.; Phu, J.V.; Fernandez, T.G.; Pavel, I.E. Nanosilver: An Old Antibacterial Agent with Great Promise in the Fight against Antibiotic Resistance. Antibiotics 2023, 12, 1264. [Google Scholar] [CrossRef] [PubMed]
  36. Mihai, M.M.; Dima, M.B.; Dima, B.; Holban, A.M. Nanomaterials for Wound Healing and Infection Control. Materials 2019, 12, 2176. [Google Scholar] [CrossRef] [PubMed]
  37. Wang, Y.-C.; Lee, H.-C.; Chen, C.-L.; Kuo, M.-C.; Ramachandran, S.; Chen, R.-F.; Kuo, Y.-R. The Effects of Silver-Releasing Foam Dressings on Diabetic Foot Ulcer Healing. J. Clin. Med. 2021, 10, 1495. [Google Scholar] [CrossRef]
  38. Varela, P.; Marlinghaus, L.; Sartori, S.; Viebahn, R.; Salber, J.; Ciardelli, G. Response of Human Macrophages to Clinically Applied Wound Dressings Loaded With Silver. Front. Bioeng. Biotechnol. 2020, 8, 124. [Google Scholar] [CrossRef]
  39. Hesketh, M.; Sahin, K.B.; West, Z.E.; Murray, R.Z. Macrophage Phenotypes Regulate Scar Formation and Chronic Wound Healing. Int. J. Mol. Sci. 2017, 18, 1545. [Google Scholar] [CrossRef]
  40. You, C.; Zhu, Z.; Wang, S.; Wang, X.; Han, C.; Shao, H. Nanosilver alleviates foreign body reaction and facilitates wound repair by regulating macrophage polarization. J. Zhejiang Univ. Sci. B 2023, 24, 510–523. [Google Scholar] [CrossRef]
  41. Singh, M.; Thakur, V.; Kumar, V.; Raj, M.; Gupta, S.; Devi, N.; Upadhyay, S.K.; Macho, M.; Banerjee, A.; Ewe, D.; et al. Silver Nanoparticles and Its Mechanistic Insight for Chronic Wound Healing: Review on Recent Progress. Molecules 2022, 27, 5587. [Google Scholar] [CrossRef] [PubMed]
  42. Khansa, I.; Schoenbrunner, A.R.; Kraft, C.T.; Janis, J.E.M. Silver in Wound Care—Friend or Foe?: A Comprehensive Review. Plast. Reconstr. Surg. Glob. Open 2019, 7, e2390. [Google Scholar] [CrossRef] [PubMed]
  43. Troeman, D.P.R.; Hazard, D.; Timbermont, L.; Malhotra-Kumar, S.; van Werkhoven, C.H.; Wolkewitz, M.; Ruzin, A.; Goossens, H.; Bonten, M.J.M.; Harbarth, S.; et al. Postoperative Staphylococcus aureus Infections in Patients With and Without Preoperative Colonization. JAMA Netw. Open 2023, 6, e2339793. [Google Scholar] [CrossRef]
  44. Shiels, S.M.; Sgromolo, N.M.; Wenke, J.C. Negative pressure wound therapy does not diminish efficacy of topical antibiotic powder in a preclinical contaminated wound model. Bone Jt. Res. 2021, 10, 149–155. [Google Scholar] [CrossRef]
  45. Hahn, H.M.; Lee, I.J.; Woo, K.-J.; Park, B.Y. Silver-Impregnated Negative-Pressure Wound Therapy for the Treatment of Lower-Extremity Open Wounds: A Prospective Randomized Clinical Study. Adv. Ski. Wound Care 2019, 32, 370–377. [Google Scholar] [CrossRef]
  46. Vieira, A.L.G.; Stocco, J.G.D.; Ribeiro, A.C.G.; Frantz, C.V. Dressings used to prevent surgical site infection in the postoperative period of cardiac surgery: Integrative review. Rev. Esc. Enferm. USP 2018, 52, e03393. [Google Scholar] [CrossRef]
  47. Sapino, G.; Lanz, L.; Roesti, A.; Guillier, D.; Deglise, S.; De Santis, G.; Raffoul, W.; di Summa, P. One-Stage Coverage of Leg Region Defects with STSG Combined with VAC Dressing Improves Early Patient Mobilisation and Graft Take: A Comparative Study. J. Clin. Med. 2022, 11, 3305. [Google Scholar] [CrossRef] [PubMed]
  48. Mo, R.; Ma, Z.; Chen, C.; Meng, X.; Tan, Q. Short- and long-term efficacy of negative-pressure wound therapy in split-thickness skin grafts: A retrospective study. Ann. Palliat. Med. 2021, 10, 2935–2947. [Google Scholar] [CrossRef]
  49. Blume, P.A.; Key, J.J.; Thakor, P.; Thakor, S.; Sumpio, B. Retrospective evaluation of clinical outcomes in subjects with split-thickness skin graft: Comparing V.A.C.® therapy and conventional therapy in foot and ankle reconstructive surgeries. Int. Wound J. 2010, 7, 480–487. [Google Scholar] [CrossRef]
  50. Sowers, K.M.; Hayden, M.R. Calcific Uremic Arteriolopathy: Pathophysiology, Reactive Oxygen Species and Therapeutic Approaches. Oxidative Med. Cell. Longev. 2010, 3, 109–121. [Google Scholar] [CrossRef]
  51. Vinereanu, I.-V.; Peride, I.; Niculae, A.; Tiron, A.T.; Caragheorgheopol, A.; Manda, D.; Checherita, I.A. The Relationship between Advanced Oxidation Protein Products, Vascular Calcifications and Arterial Stiffness in Predialysis Chronic Kidney Disease Patients. Medicina 2021, 57, 452. [Google Scholar] [CrossRef] [PubMed]
  52. Galperin, T.A.; Cronin, A.J.; Leslie, K.S. Cutaneous Manifestations of ESRD. Clin. J. Am. Soc. Nephrol. 2014, 9, 201–218. [Google Scholar] [CrossRef] [PubMed]
  53. Wu, Y.; Shen, G.; Hao, C. Negative pressure wound therapy (NPWT) is superior to conventional moist dressings in wound bed preparation for diabetic foot ulcers: A randomized controlled trial. SciVee 2023, 44, 1020–1029. [Google Scholar] [CrossRef] [PubMed]
  54. Bordianu, A.; Bobircă, F.; Pătraşcu, T. Skin Grafting in the Treatment of Diabetic Foot Soft Tissue Defects. Chirurgia 2018, 113, 644–650. [Google Scholar] [CrossRef]
  55. Turissini, J.D.; Elmarsafi, T.; Evans, K.K.; Kim, P.J. Major Risk Factors Contributing to Split Thickness Skin Graft Failure. Georget. Med. Rev. 2019, 3, 7755. [Google Scholar] [CrossRef]
  56. Lim, K.; Lim, X.; Hong, Q.; Yong, E.; Chandrasekar, S.; Tan, G.W.L.; Lo, Z.J. Use of home negative pressure wound therapy in peripheral artery disease and diabetic limb salvage. Int. Wound J. 2020, 17, 531–539. [Google Scholar] [CrossRef]
  57. Zhao, C.X.; Scher, M.; Hanks, J.E.; McLean, S.A. Full-thickness versus split-thickness skin graft reconstruction of scalp defects with and without calvarium exposure. JPRA Surg. 2023. [Google Scholar] [CrossRef]
  58. Liao, C.D.; Deccico, J.-B.; Cuzzone, D.; George, F.; Xipoleas, G.D. Interrupting Negative-pressure Wound Therapy with Dakin’s Solution Is Associated with Increased Skin Graft Survival. Plast. Reconstr. Surg. Glob. Open 2022, 10, e4724. [Google Scholar] [CrossRef]
  59. Nakamura, Y.; Fujisawa, Y.; Ishitsuka, Y.; Tanaka, R.; Maruyama, H.; Okiyama, N.; Watanabe, R.; Fujimoto, M. Negative-pressure closure was superior to tie-over technique for stabilization of split-thickness skin graft in large or muscle-exposing defects: A retrospective study. J. Dermatol. 2018, 45, 1207–1210. [Google Scholar] [CrossRef]
  60. Raffetto, J.D.; Ligi, D.; Maniscalco, R.; Khalil, R.A.; Mannello, F. Why Venous Leg Ulcers Have Difficulty Healing: Overview on Pathophysiology, Clinical Consequences, and Treatment. J. Clin. Med. 2020, 10, 29. [Google Scholar] [CrossRef]
  61. Maduba, C.C.; Nnadozie, U.U.; Modekwe, V.I.; Onah, I.I. Split Skin Graft Take in Leg Ulcers: Conventional Dressing Versus Locally Adapted Negative Pressure Dressing. J. Surg. Res. 2020, 251, 296–302. [Google Scholar] [CrossRef]
  62. Kantak, N.A.; Mistry, R.; Varon, D.E.; Halvorson, E.G. Negative Pressure Wound Therapy for Burns. Clin. Plast. Surg. 2017, 44, 671–677. [Google Scholar] [CrossRef]
  63. Salvo, P.; Dini, V.; Kirchhain, A.; Janowska, A.; Oranges, T.; Chiricozzi, A.; Lomonaco, T.; Di Francesco, F.; Romanelli, M. Sensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review. Sensors 2017, 17, 2952. [Google Scholar] [CrossRef] [PubMed]
  64. Beiner, E.; Miguel, S.B.; Friederich, H.-C.; Tesarz, J. PerPAIN Consortium Elevated high sensitive C-reactive protein in fibromyalgia. Front. Psychiatry 2023, 14, 1237518. [Google Scholar] [CrossRef] [PubMed]
  65. Legendre, C.; Debure, C.; Meaume, S.; Lok, C.; Golmard, J.L.; Senet, P. Impact of protein deficiency on venous ulcer healing. J. Vasc. Surg. 2008, 48, 688–693. [Google Scholar] [CrossRef] [PubMed]
  66. Rashid, H.U.; Rashid, M.; Sarwar, S.U.R.; Khan, I.; Khan, N.; Bibi, N. Negative Pressure Wound Therapy (NPWT): Our Experience in Pakistan With Locally Made Dressing. Cureus 2020, 12, e9464. [Google Scholar] [CrossRef] [PubMed]
  67. Liu, T.; Yang, F.; Li, Z.; Yi, C.; Bai, X. A prospective pilot study to evaluate wound outcomes and levels of serum C-reactive protein and interleukin-6 in the wound fluid of patients with trauma-related chronic wounds. Ostomy Wound Manag. 2014, 60, 30–37. [Google Scholar]
Jpm 14 00206 g001
Figure 1. Scheme of dressing methods and schedules.
Figure 1. Scheme of dressing methods and schedules.
Jpm 14 00206 g001
Jpm 14 00206 g002
Figure 2. Dynamic variation of CRP levels.
Figure 2. Dynamic variation of CRP levels.
Jpm 14 00206 g002
Jpm 14 00206 g003
Figure 3. Grafted chronic ulceration treated with the combination of NPWT and AgNPs. 1. Ulcer 2. Skin graft after 7 days 3. Skin graft after 10 days 4. Skin graft after 14 days.
Figure 3. Grafted chronic ulceration treated with the combination of NPWT and AgNPs. 1. Ulcer 2. Skin graft after 7 days 3. Skin graft after 10 days 4. Skin graft after 14 days.
Jpm 14 00206 g003
Jpm 14 00206 g004
Figure 4. Patient presented with Morel-Lavallée lesion. After debridement and progressive closure of subcutaneous degloving, we covered the remaining defect with a skin graft dressed with NPWT+AgNPs. 1. Debrided lesion 2. Skin graft imediately after surgery 3. Skin graft after 7 days 4. Skin graft after 14 days.
Figure 4. Patient presented with Morel-Lavallée lesion. After debridement and progressive closure of subcutaneous degloving, we covered the remaining defect with a skin graft dressed with NPWT+AgNPs. 1. Debrided lesion 2. Skin graft imediately after surgery 3. Skin graft after 7 days 4. Skin graft after 14 days.
Jpm 14 00206 g004
Jpm 14 00206 g005
Figure 5. Defect after melanoma excision covered with STSG and dressed with silver nanoparticle sheet. 1. Cutaneous tumor prior to excision; 2. Skin graft after 7 days; 3. Skin graft after 10 days 4. Skin graft after 14 days.
Figure 5. Defect after melanoma excision covered with STSG and dressed with silver nanoparticle sheet. 1. Cutaneous tumor prior to excision; 2. Skin graft after 7 days; 3. Skin graft after 10 days 4. Skin graft after 14 days.
Jpm 14 00206 g005
Jpm 14 00206 g006
Figure 6. Patient with extensive basal cell carcinoma of the thigh following a chronic ulceration. 1. Preoperative aspect of tumor 2. Graft managed with compressive dressing at 7 days postoperatively. 3. Graft at 10 days postoperatively. 4. Graft at 14 days postoperatively.
Figure 6. Patient with extensive basal cell carcinoma of the thigh following a chronic ulceration. 1. Preoperative aspect of tumor 2. Graft managed with compressive dressing at 7 days postoperatively. 3. Graft at 10 days postoperatively. 4. Graft at 14 days postoperatively.
Jpm 14 00206 g006
Table 1. Distribution of patients.
Table 1. Distribution of patients.
Silver Nanoparticle SheetNPWT+AgNPsTotal
Defect originPostexcisional defect171128
Ulceration debridement242852
Graft area (cm2)<150 cm2141125
150–500 cm2222042
>500 cm25813
Cardiovascular comorbiditiesNo81422
Yes332558
Diabetes mellitusNo10919
Yes313061
Table 2. Graft integration depending on type of dressing used.
Table 2. Graft integration depending on type of dressing used.
MeanStd. Deviationp-Value
Graft take after 7 days (%)Silver nanoparticle sheet74.8811.374<0.001
NPWT+AgNPs85.008.959
Graft take after 10 days (%)Silver nanoparticle sheet87.209.686<0.001
NPWT+AgNPs97.564.115
Graft take after 14 days (%)Silver nanoparticle sheet93.418.905<0.001
NPWT+AgNPs99.621.771
Table 3. Graft evolution depending on cardiovascular comorbidities.
Table 3. Graft evolution depending on cardiovascular comorbidities.
No CV DiseaseCV Disease
MeanStd. Deviationp ValueEffect SizeMeanStd. Deviationp ValueEffect Size
Graft take after 7 days (%)Silver nanoparticle sheet79.3810.5010.718−0.1624673.7911.459<0.001−1.35267
NPWT+AgNPs81.0710.41187.207.371
Graft take after 10 days (%)Silver nanoparticle sheet90.639.0390.064−0.8683886.369.785<0.001−1.52861
NPWT+AgNPs96.434.97298.203.500
Graft take after 14 days (%)Silver nanoparticle sheet93.757.9060.092−1.0749993.339.242<0.001−0.92157
NPWT+AgNPs99.292.67399.801.000
Table 4. Graft evolution depending on diabetes mellitus type 2.
Table 4. Graft evolution depending on diabetes mellitus type 2.
No DiabetesDiabetes Mellitus
MeanStd. Deviationp
Value		Effect SizeMeanStd. Deviationp ValueEffect Size
Graft take after 7 days (%)Silver nanoparticle sheet84.008.7560.098−0.804371.9410.621<0.001−1.17855
NPWT+AgNPs91.118.93783.178.251
Graft take after 10 days (%)Silver nanoparticle sheet96.004.5950.304−0.487184.359.196<0.001−1.82809
NPWT+AgNPs98.335.00097.333.880
Graft take after 14 days (%)Silver nanoparticle sheet100.000.0000.3470.485991.299.307<0.001−1.23936
NPWT+AgNPs99.441.66799.671.826
Table 5. Graft evolution depending on graft area.
Table 5. Graft evolution depending on graft area.
<150 cm2150–500 cm2>500 cm2
Meanp ValueEffect SizeMeanp ValueEffect SizeMeanp ValueEffect Size
Graft take after 7 days (%)Silver nanoparticle sheet84.290.068−0.7727472.050.000−1.4917761.000.000−3.50173
NPWT+AgNPs89.5586.2575.63
Graft take after 10 days (%)Silver nanoparticle sheet95.000.004−1.2134585.230.000−1.8181374.000.000−4.34509
NPWT+AgNPs99.5597.7594.38
Graft take after 14 days (%)Silver nanoparticle sheet98.570.218−0.4604193.180.003−0.9921180.000.002−4.90153
NPWT+AgNPs100.0099.5099.38
Table 6. Graft evolution depending on defect origin.
Table 6. Graft evolution depending on defect origin.
PostexcisionalUlceration Debridement
MeanStd. Deviationp ValueEffect SizeMeanStd. Deviationp ValueEffect Size
Graft take after 7 days (%)Silver nanoparticle sheet82.657.7290.000−1.6054569.3810.3540.000−1.3342
NPWT+AgNPs93.184.04581.798.302
Graft take after 10 days (%)Silver nanoparticle sheet93.535.5240.000−1.4931982.719.5530.000−1.90856
NPWT+AgNPs100.000.00096.614.524
Graft take after 14 days (%)Silver nanoparticle sheet98.822.8110.104−0.5334289.589.7710.000−1.45283
NPWT+AgNPs100.000.00099.462.081
Table 7. Variation of CRP depending on the type of dressing used.
Table 7. Variation of CRP depending on the type of dressing used.
MeanStd. Deviationp-Value
CRP before graft (mg/dL)Silver nanoparticle sheet4.0202.81490.868
NPWT+AgNPs3.9152.7547
CRP after 7 days (mg/dL)Silver nanoparticle sheet38.025.9850.481
NPWT+AgNPs36.977.235
CRP after 10 days (mg/dL)Silver nanoparticle sheet11.4736.53280.001
NPWT+AgNPs7.2673.9482
CRP after 14 days (mg/dL)Silver nanoparticle sheet4.1292.49210.145
NPWT+AgNPs3.3382.3040
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Abu-Baker, A.; Țigăran, A.-E.; Peligrad, T.; Ion, D.-E.; Gheoca-Mutu, D.-E.; Avino, A.; Hariga, C.-S.; Moraru, O.E.; Răducu, L.; Jecan, R.-C. Exploring an Innovative Approach: Integrating Negative-Pressure Wound Therapy with Silver Nanoparticle Dressings in Skin Graft Procedures. J. Pers. Med. 2024, 14, 206. https://doi.org/10.3390/jpm14020206

AMA Style

Abu-Baker A, Țigăran A-E, Peligrad T, Ion D-E, Gheoca-Mutu D-E, Avino A, Hariga C-S, Moraru OE, Răducu L, Jecan R-C. Exploring an Innovative Approach: Integrating Negative-Pressure Wound Therapy with Silver Nanoparticle Dressings in Skin Graft Procedures. Journal of Personalized Medicine. 2024; 14(2):206. https://doi.org/10.3390/jpm14020206

Chicago/Turabian Style

Abu-Baker, Abdalah, Andrada-Elena Țigăran, Teodora Peligrad, Daniela-Elena Ion, Daniela-Elena Gheoca-Mutu, Adelaida Avino, Cristian-Sorin Hariga, Oriana Elena Moraru, Laura Răducu, and Radu-Cristian Jecan. 2024. "Exploring an Innovative Approach: Integrating Negative-Pressure Wound Therapy with Silver Nanoparticle Dressings in Skin Graft Procedures" Journal of Personalized Medicine 14, no. 2: 206. https://doi.org/10.3390/jpm14020206

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop